IDENTIFICATION OF A NOVEL POTENTIAL TUMOR MARKER

新型潜在肿瘤标志物的鉴定

• 批准号: 6298856
• 负责人: Yu Geng
• 金额: $ 13.38万
• 依托单位: PROSCI, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-01-18 至 2001-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298856
• 关键词: biomarker; immunoaffinity chromatography; neoplasm /cancer diagnosis; neoplastic cell; nucleic acid sequence; oncoproteins; protein purification; protein structure function; tissue /cell culture; tumor antigens; western blottings

DESCRIPTION: Cancer remains the second leading cause of death in developed countries. A cancer-associated protein was recently discovered during evaluation of antibodies. This protein, like telomerase, was abundantly expressed in 85 percent of tumor cell lines and malignant tumor tissues from patients with lung, breast, brain, or kidney cancer but was detected in only 3.4 percent of normal cells and tissues. It has the features of oncofetal proteins and telomerase but is identical neither to telomerase nor to the protein from which the antibody generating peptide was selected. Thus, this protein appears to be a novel cancer antigen. The expression levels of the protein in a variety of cancer tissues, particularly lung cancer, will be characterized in this proposal. It will be identified by protein purification using a combination of immunoaffinity chromatography and 2D gel separation and sequencing of the purified protein and digested peptides, by phage expression library screening and cDNA sequencing, and by bioinformatic approach. The long-term objectives are to isolate the gene encoding this protein, to develop screening and diagnostic kits, and to define a therapeutic target for cancer. This protein has a large market potential for the development of diagnostic kits and the design of therapeutic drugs for cancer. PROPOSED COMMERCIAL APPLICATION: Characterization and Identification of this novel cancer-associated protein has potential not only in screening diagnosis, prognosis, and monitoring of cancer, but also has potential in molecular and genetic studies of tumor development as well as in being a target for cancer therapy. This novel cancer-associated protein has a large market potential for the development of reserch reagents, diagnostic kits, and therapeutic drugs for cancer.

描述：癌症仍然是发达的第二大死亡原因 国家。最近在 评估抗体。这种蛋白质，例如端粒酶，大量 在85％的肿瘤细胞系和来自的恶性肿瘤组织中表达 肺，乳房，脑或肾癌患者，但仅在 正常细胞和组织的3.4％。它具有Oncofetal的功能 蛋白质和端粒酶，但与端粒酶既不相同，也不相同 选择了产生肽的抗体的蛋白质。因此，这个 蛋白质似乎是一种新型的癌症抗原。表达水平 各种癌症组织中的蛋白质，尤其是肺癌，将是 在此提案中是特征的。它将通过蛋白质纯化来识别 结合免疫亲和力色谱和2D凝胶分离和 通过噬菌体表达进行纯化蛋白质和消化肽的测序 库筛选和cDNA测序，以及通过生物信息学方法。这 长期目标是隔离编码该蛋白质的基因，以发展 筛查和诊断套件，并定义癌症的治疗靶标。 该蛋白具有巨大的诊断发展潜力 工具包和癌症治疗药物的设计。 拟议的商业应用： 这种新型癌症相关蛋白的表征和鉴定具有潜力 不仅在筛查诊断，预后和监测癌症，而且还具有潜力 在肿瘤发育的分子和遗传研究中以及成为癌症的靶标 治疗。 这种新型癌症相关蛋白具有巨大的开发市场潜力 用于癌症的治疗试剂，诊断剂和治疗药物的。